Suppression of breast cancer metastasis using the next generation nasal spray vaccine

2014 Fiscal Year Final Research Report

• Project/Area Number: 25670441
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Endocrinology
• Research Institution: Mie University
• Principal Investigator: KAWANO Mitsuo 三重大学, 医学(系)研究科(研究院), 講師 (00234097)
• Co-Investigator(Kenkyū-buntansha): KATO Takuma 三重大学, 大学院医学系研究科, 准教授 (60224515)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: hPIV2 / 乳癌 / 遺伝子免疫療法 / 腫瘍免疫 / 免疫活性化 / 細胞性免疫 / 液性免疫 / 転移

Outline of Final Research Achievements

Recently, we have established a novel functional replication-deficient virus vector; a recombinant human parainfluenza type 2 virus vector (hPIV2): highly safe, expressive and immunogenic vector.
In this study, we have developed hPIV2 engineered to express Ag85B (hPIV2/Ag85B) and investigated antitumor effects against breast cancer metastasis by intranasal administration to a breast cancer like model mice generated by transplanting 4T1-Luc cells using the hPIV2/Ag85B. Especially, suppression effects of breast cancer metastasis were recognized in mouse lungs vaccinated high dose hPIV2/Ag85B.

Free Research Field

分子ウイルス学